论文部分内容阅读
目的探讨腹腔热灌注化疗结合免疫治疗机治疗恶性腹水的疗效及临床分析。方法 2010年7月至2012年7月期间,我院诊治的90例恶性腹水患者,随机将其分为对照组(腹腔热灌注化疗)和观察组(加用免疫治疗机治疗),每组各45例,对两组临床疗效,以及毒副作用,进行观察和比较。结果与对照组相比,观察组治疗的总有效率明显升高,治疗期间的毒副作用发生率明显降低,差异有统计学意义(P<0.05)。结论腹腔热灌注化疗结合免疫治疗机治疗恶性腹水疗效显著,明显改善患者预后质量,并且治疗期间毒副作用相对较少,患者可以较好耐受,值得临床推广。
Objective To investigate the efficacy and clinical analysis of intraperitoneal hyperthermic chemotherapy combined with immunotherapy in the treatment of malignant ascites. Methods From July 2010 to July 2012, 90 patients with malignant ascites treated in our hospital were randomly divided into control group (intraperitoneal hyperthermic chemotherapy) and observation group (treated with immunotherapy machine), each group 45 cases, the two groups of clinical efficacy, as well as side effects, were observed and compared. Results Compared with the control group, the total effective rate of the observation group was significantly increased, and the incidence of toxic and side effects during the treatment period was significantly lower (P <0.05). Conclusion Intraperitoneal hyperthermic perfusion chemotherapy combined with immunotherapy machine has significant curative effect on malignant ascites, which can obviously improve the quality of prognosis of patients and has relatively fewer side effects during treatment. Patients are well tolerated and worthy of clinical promotion.